SS-31 Study Explained: Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of

Quick answer

For “Therapeutic Peptide SS-31 Modulates Membrane,” SS-31 is a synthetic tetrapeptide that targets the inner mitochondrial membrane, where it binds to cardiolipin.¹

The result belongs to the exact population, outcome, and design described in the source. For Filipino readers, that makes SS-31 an evidence question first and a separate product-verification question second. That order keeps the short answer useful without turning it into personal guidance or a sales promise. That keeps the answer specific and easy to check.

What is SS-31, in plain language?

This Therapeutic Peptide SS-31 Modulates Membrane question becomes simpler once research and product identity are given different jobs. One explains a finding; the other identifies a catalog entry.

For “Therapeutic Peptide SS-31 Modulates Membrane,” the measured outcome was clear: the same long-term Barth syndrome study also reported improvements in three-dimensional echocardiographic measures of left ventricular stroke, end-diastolic, and end-systolic volumes.²

Within “Therapeutic Peptide SS-31 Modulates Membrane,” the source places the result in this setting: the TAZPOWER open-label extension found that 3D left ventricular stroke, end-diastolic, and end-systolic volumes improved, showing significant trends for improvement from baseline to week 168.²

For “Therapeutic Peptide SS-31 Modulates Membrane,” the practical limitation is this: these are secondary endpoint findings from a small, open-label study.²

Readers researching SS-31 can view its live catalog details below. The listing identifies the catalog item and is separate from the evidence discussed here.

What did the central study report?

That distinction keeps this Therapeutic Peptide SS-31 Modulates Membrane finding useful. A narrow result can answer a real question without becoming a promise about every person or product.

For “Therapeutic Peptide SS-31 Modulates Membrane,” the study reported that the MMPOWER-3 phase 3 trial in 218 adults with primary mitochondrial myopathy did not meet its primary endpoints for improving the six-minute walk distance or total fatigue score after 24 weeks.³

Within “Therapeutic Peptide SS-31 Modulates Membrane,” the setting matters: the MMPOWER-3 randomized, placebo-controlled trial reported that the study did not meet its primary efficacy endpoints for change in 6MWT or PMMSA total fatigue score at week 24.³

For “Therapeutic Peptide SS-31 Modulates Membrane,” the main limit is equally important: this was the overall result for a genetically diverse population.³

What does the wider evidence add?

The catalog question is separate from the Therapeutic Peptide SS-31 Modulates Membrane research question. A live card helps with navigation, while the cited source supports the scientific statement.

For “Therapeutic Peptide SS-31 Modulates Membrane,” researchers found that the same long-term Barth syndrome study also reported improvements in three-dimensional echocardiographic measures of left ventricular stroke, end-diastolic, and end-systolic volumes.²

Within “Therapeutic Peptide SS-31 Modulates Membrane,” the study design provides the frame: the TAZPOWER open-label extension found that 3D left ventricular stroke, end-diastolic, and end-systolic volumes improved, showing significant trends for improvement from baseline to week 168.²

For “Therapeutic Peptide SS-31 Modulates Membrane,” one caution belongs beside that result: these are secondary endpoint findings from a small, open-label study.²

Which limits matter most?

The point is not to make Therapeutic Peptide SS-31 Modulates Membrane sound weaker or stronger. It is to describe the finding at the same size as the source.

For “Therapeutic Peptide SS-31 Modulates Membrane,” the measured outcome was clear: the MMPOWER-3 phase 3 trial in 218 adults with primary mitochondrial myopathy did not meet its primary endpoints for improving the six-minute walk distance or total fatigue score after 24 weeks.³

Within “Therapeutic Peptide SS-31 Modulates Membrane,” the source places the result in this setting: the MMPOWER-3 randomized, placebo-controlled trial reported that the study did not meet its primary efficacy endpoints for change in 6MWT or PMMSA total fatigue score at week 24.³

For “Therapeutic Peptide SS-31 Modulates Membrane,” the practical limitation is this: this was the overall result for a genetically diverse population.³

How does the catalog identity fit?

This Therapeutic Peptide SS-31 Modulates Membrane question becomes simpler once research and product identity are given different jobs. One explains a finding; the other identifies a catalog entry.

For “Therapeutic Peptide SS-31 Modulates Membrane,” the study reported that SS-31 is a synthetic tetrapeptide that targets the inner mitochondrial membrane, where it binds to cardiolipin.¹

Within “Therapeutic Peptide SS-31 Modulates Membrane,” the setting matters: the FDA label describes FORZINITY (elamipretide) as a mitochondrial cardiolipin binder. A laboratory study notes SS-31's known property of mitochondrial inner membrane binding.¹

For “Therapeutic Peptide SS-31 Modulates Membrane,” the main limit is equally important: this is a description of its mechanism of action from regulatory and laboratory sources.¹

For “Therapeutic Peptide SS-31 Modulates Membrane,” the central finding was specific: in a long-term open-label extension of the TAZPOWER trial, people with Barth syndrome who continued elamipretide showed a cumulative improvement of 96.1 meters on the six-minute walk test over 168 weeks.⁴ For “Therapeutic Peptide SS-31 Modulates Membrane,” the finding should stop here: this was an open-label study with a small number of participants, and all knew they were receiving the active drug.⁴

For “Therapeutic Peptide SS-31 Modulates Membrane,” researchers found that WHO states that some falsified medical products can closely resemble genuine products and may require quality-control analysis.⁵ For “Therapeutic Peptide SS-31 Modulates Membrane,” one caution belongs beside that result: appearance alone cannot authenticate a product or establish a research outcome.⁵

Readers comparing this topic with MOTS-C can view its live catalog details below. It is a separate catalog reference, not a suggested combination.

What should Filipino readers take away?

That distinction keeps this Therapeutic Peptide SS-31 Modulates Membrane finding useful. A narrow result can answer a real question without becoming a promise about every person or product.

For “Therapeutic Peptide SS-31 Modulates Membrane,” researchers found that in a 12-week randomized trial of 12 males with Barth syndrome, the primary endpoints included the distance walked in six minutes and a measure of muscle strength.⁶

Within “Therapeutic Peptide SS-31 Modulates Membrane,” the study design provides the frame: the FDA snapshot summary describes the randomized portion of the SPIBA-201 trial, which evaluated efficacy in 12 patients aged ≥12 years with genetically confirmed Barth syndrome.⁶

For “Therapeutic Peptide SS-31 Modulates Membrane,” one caution belongs beside that result: the snapshot reports the trial design and endpoints but does not provide the numerical results for the primary endpoints.⁶

For “Therapeutic Peptide SS-31 Modulates Membrane,” the source describes a focused result: the Philippine FDA Verification Portal separates licensed establishments from registered or notified health products.⁷ For “Therapeutic Peptide SS-31 Modulates Membrane,” the source also narrows the conclusion: a portal record applies to the exact product or establishment named in that record.⁷

Bottom line

For “Therapeutic Peptide SS-31 Modulates Membrane,” the clearest reading is that SS-31 is a synthetic tetrapeptide that targets the inner mitochondrial membrane, where it binds to cardiolipin.¹

In the “Therapeutic Peptide SS-31 Modulates Membrane” discussion, this is a description of its mechanism of action from regulatory and laboratory sources.¹ For Filipino readers, the research result and the exact local product record remain separate checks.

That approach keeps SS-31 informative without turning one study into personal advice, a universal promise, or proof about a catalog product.

Frequently asked questions

What is the short answer about SS-31?

For “Therapeutic Peptide SS-31 Modulates Membrane,” the cited source gives a focused answer: SS-31 is a synthetic tetrapeptide that targets the inner mitochondrial membrane, where it binds to cardiolipin.¹ The conclusion stays tied to that study’s population, method, and measured outcome.

Does one positive result settle the whole topic?

For “Therapeutic Peptide SS-31 Modulates Membrane,” no single result settles the whole topic. The snapshot reports the trial design and endpoints but does not provide the numerical results for the primary endpoints.⁶ A useful result can remain narrow without being dismissed or promoted as a universal benefit.

Why does the study context matter?

Within “Therapeutic Peptide SS-31 Modulates Membrane,” the 168-week open-label extension of the TAZPOWER trial reported significant improvements from baseline on the 6MWT at all time points, with a cumulative 96.1 m improvement at week 168 (P = .003). Ten patients entered the extension, and eight completed it.⁴ Changing the population, comparison, formulation, or endpoint would change the question, so those details belong beside the finding.

What should Filipino readers verify?

For “Therapeutic Peptide SS-31 Modulates Membrane,” SS-31 is a synthetic tetrapeptide that targets the inner mitochondrial membrane, where it binds to cardiolipin.¹ Check the exact name and record shown by the official source instead of assuming that a familiar molecule name covers every listing.

Do the SS-31 and MOTS-C cards prove a benefit?

No. In this Therapeutic Peptide SS-31 Modulates Membrane guide, the cards are live catalog references for navigation. They do not prove study equivalence, turn research into a product claim, or suggest that the two items should be used together.⁸

Sources

Footnotes

1. FDA Drugs@FDA record for FORZINITY (ELAMIPRETIDE HYDROCHLORIDE); Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function.. The FDA label describes FORZINITY (elamipretide) as a mitochondrial cardiolipin binder. A laboratory study notes SS-31's known property of mitochondrial inner membrane binding. This is a description of its mechanism of action from regulatory and laboratory sources. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸

2. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.. The TAZPOWER open-label extension found that 3D left ventricular stroke, end-diastolic, and end-systolic volumes improved, showing significant trends for improvement from baseline to week 168. These are secondary endpoint findings from a small, open-label study. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶

3. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.. The MMPOWER-3 randomized, placebo-controlled trial reported that the study did not meet its primary efficacy endpoints for change in 6MWT or PMMSA total fatigue score at week 24. This was the overall result for a genetically diverse population. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶

4. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.. The 168-week open-label extension of the TAZPOWER trial reported significant improvements from baseline on the 6MWT at all time points, with a cumulative 96.1 m improvement at week 168 (P = .003). Ten patients entered the extension, and eight completed it. This was an open-label study with a small number of participants, and all knew they were receiving the active drug. ↩ ↩² ↩³

5. WHO laboratory analysis of suspected falsified medical products; WHO laboratory testing for health-product regulation. WHO guidance on suspected falsified medical products and regulatory laboratory testing. Appearance alone cannot authenticate a product or establish a research outcome. ↩ ↩²

6. FDA Drugs@FDA record for FORZINITY (ELAMIPRETIDE HYDROCHLORIDE). The FDA snapshot summary describes the randomized portion of the SPIBA-201 trial, which evaluated efficacy in 12 patients aged ≥12 years with genetically confirmed Barth syndrome. The snapshot reports the trial design and endpoints but does not provide the numerical results for the primary endpoints. ↩ ↩² ↩³ ↩⁴

7. Philippine FDA Verification Portal; FDA Advisory No. 2023-2238: Utilization of the FDA Verification Portal. Official Philippine regulatory verification service. A portal record applies to the exact product or establishment named in that record. ↩ ↩²

8. FDA Drugs@FDA record for FORZINITY (ELAMIPRETIDE HYDROCHLORIDE); Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function.; Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.; Philippine FDA Verification Portal; FDA Advisory No. 2023-2238: Utilization of the FDA Verification Portal. Editorial synthesis of the canonical research records and Philippine verification sources. This synthesis is educational and is not personal medical advice or a product recommendation. ↩